Stephen Willey Recent News
BioMarin's Carnage Could Be Buying Opportunity, Says Stifel
Downside Alert: Here's Exactly Why OncoGenex Pharma Is Having An Awful Start To December
Tetraphase's Stock Just Lost 80%, You Should Flush It...Right?
Analyst Sees No Rival Bids For Auspex Pharmaceuticals
UPDATE: Stifel Reiterates Raises PT On Cempra On Good Risk/Reward Profile
UPDATE: Stifel Reiterates On MacroGenics On Strategic Development Shift
UPDATE: Stifel Reiterates On Ophthotech Corp Following 3Q14 Report
UPDATE: Stifel Reiterates On Tekmira Pharmaceuticals Ahead Of Analyst Day
UPDATE: Stifel Reiterates On Genocea Biosciences On Attractive Risk/Reward
UPDATE: Stifel Reiterates On Dicerna Pharmaceuticals As DCR-MYC Is Progressing Nicely
UPDATE: Stifel Reiterates On NewLink Genetics On Good Risk/Reward
UPDATE: Stifel Initiates Coverage On Applied Genetic Technologies Corporation On Good Market Position
UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion
UPDATE: Stifel Initiates Coverage on Dicerna Pharmaceuticals on Riding the RNAi Wave
UPDATE: Stifel Initiates Coverage on Tekmira, Notes "Enthusiasm" for RNAi
Stifel Maintains on InterMune
UPDATE: Stifel Nicolaus Initiates Coverage on Ocera Therapeutics on Best-In-Class Mechanism of Action
UPDATE: Stifel Initiates Coverage on Relypsa on Palatable Risk and Large Market Opportunity
UPDATE: Stifel Downgrades ViroPharma Following News of Proposed Acquisition by Shire Pharmaceuticals
UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen
UPDATE: Stifel Reiterates on Conatus Pharmaceuticals on HCV-POLT Strategy Shift
UPDATE: Stifel Initiates Coverage on Ophthotech on Multiple Positive Factors
UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate Risk/Reward, Expected Slower Data Flow